Inhibrx, Inc. Common Stock
INBX
INBX was delisted on the 29th of May, 2024.
106 hedge funds and large institutions have $935M invested in Inhibrx, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 39 increasing their positions, 30 reducing their positions, and 16 closing their positions.
1,995% more call options, than puts
Call options by funds: $3.19M | Put options by funds: $152K
35% more capital invested
Capital invested by funds: $692M → $935M (+$244M)
30% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 108 → 106 (-2)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$28.3M |
| 2 |
JP Morgan Chase
New York
|
+$7.63M |
| 3 |
BlackRock
New York
|
+$4.99M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.8M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$2.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$22.5M |
| 2 |
Millennium Management
New York
|
-$12.6M |
| 3 |
State Street
Boston,
Massachusetts
|
-$6.04M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$5.75M |
| 5 |
Renaissance Technologies
New York
|
-$2.83M |
INBX Hedge Fund Activity: Q2 2023 in Review
106 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Inhibrx, Inc. Common Stock (INBX) for Q2 2023, worth a combined $935M — up 35% from $692M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of INBX and 14 opened new positions — a net loss of 2 holders — while 30 trimmed existing stakes and 39 added.
The largest buyer was Woodline Partners, adding an estimated $28.3M. The largest seller was MPM BioImpact, exiting entirely with an estimated $22.5M sold.
- 106 institutional investors held Inhibrx, Inc. Common Stock (INBX) as of Q2 2023, down from 108 in Q1 2023.
- Funds reported $935M of Inhibrx, Inc. Common Stock stock for Q2 2023, up 35% quarter-over-quarter.
- 14 funds opened new Inhibrx, Inc. Common Stock positions in Q2 2023 and 16 closed out, a net change of -2 holders.
- The largest Inhibrx, Inc. Common Stock buyer in Q2 2023 was Woodline Partners, an estimated $28.3M added.
- The largest Inhibrx, Inc. Common Stock seller in Q2 2023 was MPM BioImpact, an estimated $22.5M sold.
Based on aggregated 13F filings for Q2 2023.